Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Operating Expenses (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Operating Expenses for 10 consecutive years, with $13.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 58.34% year-over-year to $13.4 million, compared with a TTM value of $87.4 million through Sep 2025, down 18.77%, and an annual FY2024 reading of $121.3 million, up 47.43% over the prior year.
  • Operating Expenses was $13.4 million for Q3 2025 at Spero Therapeutics, down from $16.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $36.8 million in Q4 2024 and bottomed at $13.4 million in Q3 2025.
  • Average Operating Expenses over 5 years is $24.0 million, with a median of $23.7 million recorded in 2021.
  • The sharpest move saw Operating Expenses soared 98.03% in 2023, then tumbled 58.34% in 2025.
  • Year by year, Operating Expenses stood at $30.2 million in 2021, then dropped by 28.86% to $21.5 million in 2022, then rose by 6.85% to $23.0 million in 2023, then surged by 59.93% to $36.8 million in 2024, then crashed by 63.67% to $13.4 million in 2025.
  • Business Quant data shows Operating Expenses for SPRO at $13.4 million in Q3 2025, $16.6 million in Q2 2025, and $20.6 million in Q1 2025.